One year on from Vespa Capital’s investment, FibroFind, the pioneering, research-led CRO has made strong progress in building on its foundation to support the next phase of scalable growth.

The business has continued to strengthen its scientific excellence and standing, while adding the commercial, operational and financial capabilities required to position FibroFind on its mission to become the go-to translational model for biotech and pharma to de-risk their molecule and therapeutic assets.

At the time of investment, FibroFind had already established a strong reputation for its proprietary Precision Cut Tissue Slice (‘PCTS’) platform, which enables biotech and pharma customers to generate more predictive pre-clinical data using living human tissue. Since then, the business has continued to build on this scientific foundation while putting in place the people, processes and infrastructure required to support its next phase of growth.

Vespa Capital has worked closely with the management team to strengthen the organisation across several key areas. A finance director has been appointed and a new in-house finance function established, bringing improved reporting, governance and forecasting discipline to the business. This has provided a stronger platform for decision-making as the business scales.

The team has also made significant progress in expanding FibroFind’s proprietary tissue supply network, including the addition of new access arrangements and the appointment of a Chief Medical Officer to support the long-term development of this critical capability. In parallel, Vespa Capital has supported further investment in automation across the laboratory workflow, improving efficiency, consistency and capacity as demand for the company’s services continues to grow.

A major focus over the year has been the development of a more proactive commercial capability. With Vespa Capital’s support, the business has begun building a dedicated commercial function, including the appointment of a Chief Business Officer, to increase market awareness and broaden customer reach.

Looking ahead, FibroFind is well positioned for continued growth, supported by a stronger platform, broader tissue access, greater automation and a more proactive commercial capability. Vespa Capital remains excited to support the team as the business expands its reach and strengthens its position in advanced human tissue testing.

Vespa Capital Supports FibroFind’s Next Phase of Growth